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Zilver PTXCoronary late stent thrombosis following drug-eluting stent
(DES) implantation is one of the concerns in percutaneous
coronary intervention [1]. Late stent thrombosis is more frequently
observed in the ﬁrst-generation DES such as the sirolimus-eluting
stent (Cypher, Cordis Corp., Miami Lakes, FL, USA) and paclitaxel-
eluting stent (Taxus, Boston Scientiﬁc, Natick, MA, USA) as
compared to the second-generation DES such as the everolimus-
eluting stent [2,3]. Furthermore, mechanism of stent thrombosis is
different between the sirolimus-eluting stent and paclitaxel-
eluting stent [4]. Human autopsy studies revealed that hypersen-
sitivity reaction was the unique cause of late stent thrombosis with
sirolimus-eluting stents, whereas excessive ﬁbrin accumulation
was mainly observed in paclitaxel-eluting stents [4]. On the other
hand, there are few reports regarding human pathology of late
stent thrombosis following DES implantation in peripheral artery
disease.
In this issue of Journal of Cardiology Cases, Soga et al. report a
case of late stent thrombosis after paclitaxel-eluting stent
implantation for superﬁcial femoral artery disease [5]. Their
stents were self-expandable nitinol stents with 3 mg/mm2
polymer-free paclitaxel coating on the outer surfaces (Zilver
PTX, Cook Medical, Bloomington, IN, USA) [6]. The main difference
between Taxus and Zilver PTX is the presence of polymer, which
can induce prothrombotic environment leading to late stent
thrombosis [7,8]. Therefore, polymer-free Zilver PTX is consid-
ered to be safe for peripheral artery disease [9]. Also, the
randomized clinical trial showed superiority of Zilver PTX over
percutaneous transluminal angioplasty and provisional bare-
metal stent placement [10]. Nevertheless, the pathology of
stent thrombosis in their report is similar to the pathology of
Taxus stent thrombosis, showing excessive ﬁbrin accumulation
around stent struts (Fig. 1) [4]. Excessive ﬁbrin accumulationDOI of original article: http://dx.doi.org/10.1016/j.jccase.2014.10.002
http://dx.doi.org/10.1016/j.jccase.2014.11.003
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to stent thrombosis. Furthermore, their case had developed stent
thrombosis under the continuation of dual-antiplatelet therapy
and anticoagulation therapy (prothrombin time-international
normalized ratio = 3.13).
Being ‘‘polymer-free’’ may not be enough to prevent stent
thrombosis, because paclitaxel itself can prevent arterial
healing. Paclitaxel has a dose-dependent inhibitory effect on
human arterial smooth muscle cell, and the antiproliferative
potential of paclitaxel is sustained over 14 days even after a brief
single contact (20 min) [11]. Although Dake et al. reported that
the local paclitaxel levels in the arterial wall can be sustained
for 56 days in normal porcine arteries [9], there are no data
regarding the local paclitaxel levels in the human atheroscle-
rotic arterial wall in the chronic phase. The pharmacokinetics
of local paclitaxel in atherosclerotic human arteries would be
different from that in normal porcine arteries. Moreover,
vascular endothelial cells normally provide an efﬁcient barrier
against thrombosis, lipid uptake, and inﬂammation, whereas
endothelium that has regenerated after stent implantation,
especially DES, is incompetent in terms of its integrity and
function, with poorly formed cell junctions, reduced expression
of antithrombotic molecules, and decreased nitric oxide
production [12].
As compared to stent thrombosis in coronary artery disease,
detection and diagnosis of stent thrombosis in peripheral artery
disease would be more difﬁcult. While probable, possible, and
deﬁnite coronary stent thrombosis are classiﬁed based on the
Academic Research Consortium criteria [13], there are no
standard criteria regarding stent thrombosis in peripheral arterial
disease. In addition, pathological assessment of stent thrombosis
is rarely performed, because retrieving stented segments can be
done only when the patient’s limb was amputated. The case report
by Soga et al. is valuable to help vascular interventionalists to
understand the underlying pathophysiology of stent thrombosis
in superﬁcial femoral artery disease. Excessive ﬁbrin accumula-
tion around stent struts caused by polymer-free Zilver PTX stent
was similar to the pathology of coronary stent thrombosis by
Taxus stent.ess under CC BY-NC-ND license.
Fig. 1.
Histologic sections from a paclitaxel-eluting stent (PES) showing malapposition. A 69-year-old man who received a PES in a saphenous vein graft died suddenly
3 months after stent placement. Histologic sections showed thrombotic occlusion in the PES (a, b); note the malapposition secondary to severe ﬁbrin deposition
(c). A 48-year-old man with a PES implant in the proximal left anterior descending artery died suddenly at 40 months. Histologic sections showed thrombotic
occlusion of the PES (d). Most struts are malapposed with ﬁbrin deposition underneath the stent struts (e, f). Thr, thrombus.
Reproduced with permission from Nakazawa et al. [4].
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